NVB 302

Drug Profile

NVB 302

Alternative Names: NVB302

Latest Information Update: 01 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novacta Biosystems
  • Developer Novacta
  • Class Antibacterials; Bacteriocins; Peptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Clostridium-difficile-infections

Most Recent Events

  • 01 Feb 2018 Discontinued - Phase-I for Clostridium difficile infections (In volunteers) in United Kingdom (PO)
  • 28 Jan 2018 No recent reports of development identified for phase-I development in Clostridium difficile infections(In volunteers) in United Kingdom (PO)
  • 22 Jan 2016 NVB 302 is still in phase I development for Clostridium difficile infections in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top